EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Prajwol Shrestha, Steven Kao, Veronica K Cheung, Wendy A Cooper, Nico van Zandwijk, John E J Rasko, Dannel Yeo iD

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2025. Verfasst von Prajwol Shrestha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Li Ka Shing Cell and Gene Therapy Program, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Precision Medicine, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tour de Cure, National Health and Medical Research Council, Li Ka Shing Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5‐year survival of < 7%, despite the addition of immunotherapy to first‐line chemotherapy. Specific tumor biomarkers, such as delta‐like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious, novel immunomodulating targeted treatments like bispecific T‐cell engaging monoclonal antibodies (tarlatamab) and chemotherapy with PARP inhibitors. However, obtaining a tissue biopsy sample can be challenging in SCLC. Circulating tumor cells (CTCs) have the potential to provide molecular insights into a patient's cancer through a “simple” blood test. CTCs have been studied for their prognostic ability in SCLC; however, their value in guiding treatment decisions is yet to be elucidated. This review explores novel and promising targeted therapies in SCLC, summarizes current knowledge of CTCs in SCLC, and discusses how CTCs can be utilized for precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingPrecision MedicineLung NeoplasmsSmall Cell Lung CarcinomaHumansBiomarkers, TumorMolecular Targeted Therapy

Stichwörter der Autor:innen

DLL3liquid biopsyschlafen11targeted therapiestarlatamabthoracic oncology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Li Ka Shing Cell and Gene Therapy Program, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.
  • Precision Oncology Program, Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Camperdown, Australia.
  • Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.
  • Faculty of Medicine and Health, University of Sydney, Australia.
  • Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.
  • Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, Australia.

ORCID-Profile: Dannel Yeo

Förderung

  • Tour de Cure
  • National Health and Medical Research Council
  • Li Ka Shing Foundation
  • Sydney Cancer Institute Seed Grant
  • Cancer Institute New South Wales
  • Cancer Institute NSW

Zitieren

APA

Shrestha, P., Kao, S., Cheung, V. K., Cooper, W. A., van Zandwijk, N., Rasko, J. E. J., & Yeo, D. (2025). Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. Molecular Oncology. https://doi.org/10.1002/1878-0261.13696

Vancouver

Shrestha P, Kao S, Cheung VK, Cooper WA, van Zandwijk N, Rasko JEJ, et al. Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. Molecular Oncology. 2025. doi:10.1002/1878-0261.13696

BibTeX
@article{Shrestha2025,
  author = {Shrestha, Prajwol and Kao, Steven and Cheung, Veronica K and Cooper, Wendy A and van Zandwijk, Nico and Rasko, John E J and Yeo, Dannel},
  title = {Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13696}
}
Kostenlos starten →